Covid19.

Description. Size 20.

Covid19

Description. Size 20.

INTRODUCTION TO COVID-19

DATA ANALYSIS AND FORECASTS

TREATMENTS AND VACCINES

VIRUS AND ANTIBODY TESTS

OVERVIEW BY COUNTRY

SUPPORT TO WORKS

All fields are requested.

DATA ANALYSIS

MODELING

DATA FITTING

TREATMENTS AND VACCINES

SANOFI

GILEAD

BIONTECH

JOHNSON&JOHNSON

ABBVIE

VACCITECH

REGENERON

ASCLETIS

TAKEDA

HOTH TERAPEUTICS

MODERNA

CANSINOBIO

CUREVAC

NOVAVAX

Treatment+vaccine

Treatment

Treatment+vaccine

Vaccine

Treatment

Vaccine

Treatment

Treatment

Treatment

Vaccine

Vaccine

Vaccine

Vaccine

Vaccine

Plaquenil

Remdesivir

New RNA vaccine

Covid19 vaccine

lopinavir/ritonavir combination

lopinavir/ritonavir combination

Monoclonal antibody therapy

Combination of two antivirals

Polyclonal antibody therapy

Self-assembling vaccine (SAV)

mRNA-1273

Covid19 vaccine

mRNA (?)

(?)

Preclinical

III

Preclinical

Preclinical

III

IIb

Preclinical

I

Preclinical

Preclinical

I

I

Preclinical (?)

Preclinical

DATA ANALYSIS

MODELING

DATA FITTING

COVID AND ANTIBODY TESTS

SIEMENS HEALTHINEERS

WORLD NANO FOUNDATION

Covid test kit

FTD SARS-Cov-2 Array

Preclinical

DATA ANALYSIS

MODELING

DATA FITTING

NEWS ON PHARMA

Description. Size 20.

JOHNSON&JOHNSON. On Feb. 11, J&J said it is working with BARDA to test its vaccine candidate, with both organizations providing funding for research and development and the public-health organization funding the Phase 1 trials. Similar to GSK, J&J’s AdVac and PER. C6 technologies are used to improve the development process for a vaccine and were also used to develop J&J’s experimental Ebola vaccine. “We are also in discussions with other partners, that if we have a vaccine candidate with potential, we aim to make it accessible to China and other parts of the world,” Dr. Paul Stoffels, J&J’s chief scientific officer, said in a statement. On March 13, J&J said it started preclinical testing on multiple candidates in collaboration with Beth Israel Deaconess Medical Center in Boston, and it aims to have a vaccine candidate by the end of the month. J&J also said in February that it partnered with BARDA on a project that aims to screen existing antiviral medications, including experimental or approved therapies, that may be effective against COVID-19.

MODERNA. Moderna received funding from CEPI in January to develop an mRNA vaccine against COVID-19. On Feb. 24, it said it had shipped the first batch of mRNA-1273 to the NIAID for a Phase 1 clinical trial in the U.S.

PFIZER. On March 17, Pfizer announced that it would help develop and distribute BioNTech SE’s COVID-19 vaccine candidate, though the deal excludes China. BioNTech plans to put the vaccine candidate into clinical trials in late April, in Germany and the U.S. It is testing the vaccine in collaboration with Shanghai Fosun Pharmaceutical Group Co. Ltd. in China. Pfizer and BioNTech for several years have said they would partner to develop mRNA-based influenza vaccines.

GILEAD. Gilead is a longtime drugmaker best known for developing the first major cure for hepatitis-C in Sovaldi, a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing. The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis (PrEP), its preventive HIV medicine. Along with U.S. trials, Gilead is conducting a randomized, controlled clinical trial in Wuhan, testing remdesivir as a treatment for mild to moderate forms of pneumonia in people with the virus. The trial was given the go-ahead by China’s Food and Drug Administration in February.

GSK. is another leading vaccine maker, having brought to market vaccines for human papillomavirus (HPV) and the seasonal flu, among others. On Feb. 3, it said the CEPI-funded University of Queensland will have access to the British drugmaker’s vaccine adjuvant platform technology, which is believed to both strengthen the response of a vaccine and limit the amount of vaccine needed per dose. On Feb. 24, GSK said that Clover Biopharmaceuticals Inc., a Chinese biotechnology company, is also using its adjuvant technology in combination with its vaccine candidate, COVID-19 S-Trimer, in preclinical studies. Dr. Thomas Breuer, chief medical officer for GSK Vaccines, is leading work on vaccines and the adjuvant platform.

NOVAVAX. Novavax, a preclinical biotechnology company, announced Feb. 26 it had several vaccine candidates in preclinical animal studies, and that it plans to initiate a Phase I clinical study by June. In March the company it had received $4 million from CEPI to develop a COVID-19 vaccine and that Emergent BioSolutions Inc. US:EBS would support contract development and manufacturing for the experimental vaccine.

SANOFI AVENTIS. The FDA previously approved Kevzara, a treatment developed by Regeneron and Sanofi, as a therapy for rheumatoid arthritis in 2017 and that could be used for Covid. Sanofi is also working on a vaccine. Starting Feb. 18, Sanofi is working with BARDA to test a preclinical vaccine candidate for severe acute respiratory syndrome (SARS) for COVID-19 using its recombinant DNA platform. It has a long history of producing vaccines in its Sanofi Pasteur business and acquired this candidate through its 2017 acquisition of Protein Sciences for $750 million. The French drugmaker previously worked with the organization on flu vaccines. Scientists in Meriden, Ct., are working on the vaccine; David Loew, Sanofi Pasteur’s EVP, is leading the project.

ROCHE. Roche’s Actemra is a treatment first approved in 2010 as a rheumatoid arthritis drug. The Swiss drugmaker has initiated a Phase 3 clinical trial evaluating Actera as a treatment for patients with COVID-19 who have been hospitalized with severe pneumonia. Roche expects to begin enrolling around 330 patients in early April, in the U.S. and elsewhere in the world. The company plans to examine patient mortality and need for mechanical ventilation or an intensive care unit stay among other primary and secondary endpoints. The trial is in partnership with BARDA.

VAXART. Was one of the first companies to announce plans to develop a vaccine when it did so Jan. 31. In March the clinical-stage company announced that Emergent BioSolutions will help develop and manufacture its oral vaccine candidate. “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign,” Vaxart CEO Wouter Latour said in a March 18 news release. The company plans to start a Phase 1 clinical trial in the U.S. in the second half of 2020, a company executive said.

HEAT BIOLOGICS. has previously announced that it is developing a vaccine for the novel coronavirus with the University of Miami Miller School of Medicine. It disclosed March 17 in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines. The company also recently joined the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its COVID-19 vaccine, according to Maxim Group analysts.

TAKEDA. the Japanese drugmaker said March 4 it plans to test hyperimmune globulins for people who are at high risk for infection. As part of its research, which will be performed in Georgia, Takeda said it would need access to plasma from people who have recovered from COVID-19 or those who have received a vaccine if one is developed. Dr. Rajeev Venkayya, president of Takeda’s vaccine business, is the co-lead of the company’s COVID-19 response team. Like J&J, Takeda plans to examine whether other therapies, both experimental or with regulatory approval, may have treatment potential.

INOVIO. Develops immunotherapies and vaccines but hasn’t yet had a product approved for treatment. For INO-4800, preclinical testing was performed between Jan. 23 and Feb. 29. The company plans to begin clinical trials in the U.S. with 30 participants in April. It also plans to launch human trials in China and South Korea that same month, and says that it has a total of 3,000 doses prepared for the trials in the three countries. Inovio said it expects to have the first results from the trial in the fall and to have 1 million does of the vaccine ready for additional clinical trials or emergency use by the end of the year. Inovio on March 12 announced a $5 million grant from the Bill & Melinda Gates Foundation to test a delivery device for its vaccine candidate. RBC analyst Gregory Renza recently downgraded the stock to sector perform from outperform on valuation grounds and said he believed in the technology.

 


 

Raj Gorla. CONTINEO. Is partnering with MyDoc to enable providers triage and consult with high risk patients during the Covid-19 pandemic. If you are a health system or an individual provider in need of a Telehealth solution or facing bandwidth challenges with your existing platform, please reach out to us immediately.

Nina Patrick. MIPROBES. MiProbes makes cell-free biosensors to target proteins and signaling molecules from pathogens and viruses. We are currently in the process of adapting our technology for CoVID19.

Chiara Masci. HUPROCESS. Is helping companies to digitalize and solve the Covid19 issues.

PISCHOOL. They have a call to provide AI support for free to companies to fight Covid19. https://picampus-school.com/

Prashant Warier. QURE.AI Providea an AI solution to recognize cancer from RX. It is currently employed to recognize covid19 lung damage. They recently partnered with Moderna.

Nathan Mcnally. P4 PRECISION MEDICINE ACCELERATOR. Is involved in few programs to support. For example writing grants proposals for startups applying for technologies against Covid.

SOSV. Accelerator has started an invesment round on startups to fight Coronavirus.

GRANTEY is helping with Grant writing to apply for startup Covid19 funds.

OXVENT. Oxford University is preparing a ventilation collaboration for hospitals: https://oxvent.org/

SOFTSERVE. Donated 360.000$ to Ukrainian healtcare to fight Covid19.

DATA ANALYSIS

MODELING

DATA FITTING

HOW TO READ THE DATA?

Description. Size 20.

Data are data, but without an analysis they provide no insight. When analyzing the data it is important how they are sampled, labeled, and to what population they belong. It may happen that mix data belonging to two sets that cannot be compared and then the outcome may therefore be wrong. We explain how to read data on infected, intensive care unit (ICU) patients and deaths,

NUMBER OF PERSONS INFECTED OR TESTED

What we often read reported as the number of infected is actually the number of persons who have been tested and did result positive to the SARS-cov-2 virus test. This number is not relevant by itself. It has to be put together with another number, that is the total number of tested persons. And this makes sence in reference to the full number of people in a city or country.

If, for example, in a city there are 4 million people, only 1 million people have been tested, and only 200.000 people did result positive, this is a factor of 1/5th of total people tested, and 1/20th of total population. However, we have no information about the remaining 3 million people that has not been tested. Therefore, the true number of infected people may be quite higher, but it is not possible to know without testing all the population. This can be done only locally in small cities or countries.

This is why it is important to understand which strategy used each country to test the population. In most of the countries, only people who have symptomps and contact the hospitals are tested. Countries that test only people who show symptomps will show a number that grows proportionally to the full number of

NUMBER OF ICU PATIENTS (RELIABLE)

NUMBER OF DEATHS (PARTIALLY RELIABLE)

The number of

MORTALITY RATE (UNRELIABLE)

Mortality rate is another number that has to

Copyright 2020 © Goldmarck Ventures Limited